- Home
- LAC vs OCS Comparison
LAC vs OCS Comparison
Compare LAC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAC
- OCS
- Stock Information
- Founded
- LAC 2023
- OCS 2003
- Country
- LAC Canada
- OCS Switzerland
- Employees
- LAC N/A
- OCS N/A
- Industry
- LAC Metal Mining
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- LAC Basic Materials
- OCS Health Care
- Exchange
- LAC Nasdaq
- OCS Nasdaq
- Market Cap
- LAC 666.1M
- OCS 689.8M
- IPO Year
- LAC N/A
- OCS N/A
- Fundamental
- Price
- LAC $2.68
- OCS $18.27
- Analyst Decision
- LAC Hold
- OCS Strong Buy
- Analyst Count
- LAC 7
- OCS 4
- Target Price
- LAC $4.41
- OCS $30.25
- AVG Volume (30 Days)
- LAC 4.2M
- OCS 48.2K
- Earning Date
- LAC 05-12-2025
- OCS 05-07-2025
- Dividend Yield
- LAC N/A
- OCS N/A
- EPS Growth
- LAC N/A
- OCS N/A
- EPS
- LAC N/A
- OCS N/A
- Revenue
- LAC N/A
- OCS $757,024.00
- Revenue This Year
- LAC N/A
- OCS $57.00
- Revenue Next Year
- LAC N/A
- OCS $1,820.89
- P/E Ratio
- LAC N/A
- OCS N/A
- Revenue Growth
- LAC N/A
- OCS N/A
- 52 Week Low
- LAC $2.02
- OCS $10.79
- 52 Week High
- LAC $5.20
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- LAC 47.48
- OCS 52.53
- Support Level
- LAC $2.60
- OCS $14.00
- Resistance Level
- LAC $2.83
- OCS $16.39
- Average True Range (ATR)
- LAC 0.21
- OCS 0.94
- MACD
- LAC 0.01
- OCS 0.22
- Stochastic Oscillator
- LAC 67.27
- OCS 71.40
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, that is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass recently began construction and is expected to begin production in the mid- to late 2020s. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.